{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:35:20Z","timestamp":1780414520370,"version":"3.54.1"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 HD HD070611"],"award-info":[{"award-number":["R21 HD HD070611"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 MH104603-01"],"award-info":[{"award-number":["R01 MH104603-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.neuropharm.2018.05.013","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T06:51:07Z","timestamp":1526021467000},"page":"55-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Repurposing steroidogenesis inhibitors for the therapy of neuropsychiatric disorders: Promises and caveats"],"prefix":"10.1016","volume":"147","author":[{"given":"Roberto","family":"Frau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bortolato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.05.013_bib1","unstructured":"Adis Insight, 2000. https:\/\/adisinsight.springer.com\/drugs\/800009929 (Accessed 26 April 2018)."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1677\/joe.1.06375","article-title":"Cytochrome b5 modulation of 17\u03b1 hydroxylase and 17\u201320 lyase (CYP17) activities in steroidogenesis","volume":"187","author":"Akhtar","year":"2005","journal-title":"J.\u00a0Endocrinol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/phar.1612","article-title":"Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: a pharmacovigilance study","volume":"35","author":"Ali","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib4","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1346-8138.2002.tb00200.x","article-title":"Depression circumstantially related to the administration of finasteride for androgenetic alopecia","volume":"29","author":"Altomare","year":"2002","journal-title":"J.\u00a0Dermatol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0079-6123(01)32096-4","article-title":"Astroglia play a key role in the neuroprotective actions of estrogen","volume":"132","author":"Azcoitia","year":"2001","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/03602530802431439","article-title":"The aldo-keto reductase superfamily and its role in drug metabolism and detoxification","volume":"40","author":"Barski","year":"2008","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib7","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1210\/jc.2016-2726","article-title":"Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss","volume":"101","author":"Basaria","year":"2016","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib8","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1523\/JNEUROSCI.1532-16.2016","article-title":"Sex-dependent regulation of aromatase-mediated synaptic plasticity in the basolateral amygdala","volume":"37","author":"Bender","year":"2017","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib9","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/jne.12066","article-title":"The implication of neuroactive steroids in Tourette's syndrome pathogenesis: a role for 5\u03b1-reductase?","volume":"25","author":"Bortolato","year":"2013","journal-title":"J.\u00a0Neuroendocrinol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib10","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1038\/npp.2008.39","article-title":"Antipsychotic-like properties of 5-alpha-reductase inhibitors","volume":"33","author":"Bortolato","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib11","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1176\/appi.ajp.2007.07060978","article-title":"Treatment of Tourette's syndrome with finasteride","volume":"164","author":"Bortolato","year":"2007","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0920-9964(00)00139-0","article-title":"Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia","volume":"49","author":"Braff","year":"2001","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11940-000-0014-1","article-title":"Obsessive-compulsive disorder and Tourette's syndrome","volume":"2","author":"Buzan","year":"2000","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib14","first-page":"2620","article-title":"Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer","volume":"7","author":"Buzdar","year":"2001","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib15","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/cncr.10908","article-title":"An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane","volume":"95","author":"Buzdar","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neubiorev.2011.04.012","article-title":"The mesoaccumbens dopamine in coping with stress","volume":"36","author":"Cabib","year":"2012","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib17","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1523\/JNEUROSCI.19-12-05044.1999","article-title":"OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons","volume":"19","author":"Campbell","year":"1999","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cell.2010.06.001","article-title":"SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder","volume":"142","author":"Cantagrel","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2017.11.014","article-title":"Preface Drug discovery in neurodegenerative disorders: a defeat for pharmacology?","volume":"817","author":"Caraci","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib20","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/cncr.21339","article-title":"New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma","volume":"104","author":"Carlini","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0006-3223(95)00101-8","article-title":"Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results","volume":"39","author":"Castellanos","year":"1996","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.psyneuen.2012.06.008","article-title":"Regional distribution of 5\u03b1-reductase type 2 in the adult rat brain: an immunohistochemical analysis","volume":"38","author":"Castelli","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/153537020222700603","article-title":"Decrease of core body temperature in mice by dehydroepiandrosterone","volume":"227","author":"Catalina","year":"2002","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0361-9230(97)00216-5","article-title":"Steroid metabolism in the mammalian brain: 5alpha-reduction and aromatization","volume":"44","author":"Celotti","year":"1997","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib25","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1210\/en.2005-0263","article-title":"Dehydroepiandrosterone sulfate and allopregnanolone directly stimulate catecholamine production via induction of tyrosine hydroxylase and secretion by affecting actin polymerization","volume":"146","author":"Charalampopoulos","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib26","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/jc.2003-030330","article-title":"Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor","volume":"89","author":"Clark","year":"2004","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib27","first-page":"915","article-title":"Inhibitors of 5\u03b1-reductase-related side effects in patients seeking medical care for sexual dysfunction","volume":"35","author":"Corona","year":"2012","journal-title":"J.\u00a0Endocrinol. Invest."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1741-7015-11-126","article-title":"Toward the future of psychiatric diagnosis: the seven pillars of RDoC","volume":"11","author":"Cuthbert","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib29","doi-asserted-by":"crossref","first-page":"R263","DOI":"10.1530\/EJE-14-1014","article-title":"Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome","volume":"172","author":"Daniel","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0006-8993(02)02290-4","article-title":"Depletion of cortical allopregnanolone potentiates stress-induced increase in cortical dopamine output","volume":"932","author":"Dazzi","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib31","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.euroneuro.2013.05.012","article-title":"Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder","volume":"23","author":"Denys","year":"2013","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib32","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.psyneuen.2011.09.018","article-title":"Inhibition of 5\u03b1-reductase in the nucleus accumbens counters sensorimotor gating deficits induced by dopaminergic activation","volume":"37","author":"Devoto","year":"2012","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1515\/REVNEURO.1994.5.1.27","article-title":"Modulation of brain dopamine transmission by sex steroids","volume":"5","author":"Di Paolo","year":"1994","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/(SICI)1097-0045(19981001)37:2<77::AID-PROS3>3.0.CO;2-I","article-title":"Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia","volume":"37","author":"Di Silverio","year":"1998","journal-title":"Prostate"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J.\u00a0Health Econ."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.yhbeh.2012.04.003","article-title":"Effects of estradiol in adult neurogenesis and brain repair in zebrafish","volume":"63","author":"Diotel","year":"2013","journal-title":"Horm. Behav."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib37","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.neuropharm.2006.10.015","article-title":"Neurosteroid dehydroepiandrosterone sulfate enhances spontaneous glutamate release in rat prelimbic cortex through activation of dopamine D1 and sigma-1 receptor","volume":"52","author":"Dong","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib38","first-page":"550","article-title":"The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia","volume":"41","author":"Drake","year":"1999","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib39","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1006\/bbrc.1996.1684","article-title":"Molecular cloning of human type 3 3 alpha-hydroxysteroid dehydrogenase that differs from 20 alpha-hydroxysteroid dehydrogenase by seven amino acids","volume":"228","author":"Dufort","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1742-2094-8-81","article-title":"Neuroinflammation induces glial aromatase expression in the uninjured songbird brain","volume":"8","author":"Duncan","year":"2011","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib41","first-page":"877","article-title":"Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial","volume":"174","author":"Etzioni","year":"2005","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1210\/jc.2012-3126","article-title":"Medical treatment of Cushing's disease","volume":"98","author":"Feelders","year":"2013","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0166-4328(99)00082-0","article-title":"Androgen actions on central serotonin neurotransmission: relevance for mood, mental state and memory","volume":"105","author":"Fink","year":"1999","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib44","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.schres.2015.04.044","article-title":"Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress","volume":"168","author":"Frau","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib45","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.psyneuen.2013.09.014","article-title":"Inhibition of 17\u03b1-hydroxylase\/C17,20 lyase reduces gating deficits consequent to dopaminergic activation","volume":"39","author":"Frau","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib46","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1038\/npp.2017.13","article-title":"The neurosteroidogenic enzyme 5\u03b1-reductase mediates psychotic-like complications of sleep deprivation","volume":"42","author":"Frau","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.psyneuen.2015.09.014","article-title":"The neurosteroidogenic enzyme 5\u03b1-reductase modulates the role of D1 dopamine receptors in rat sensorimotor gating","volume":"63","author":"Frau","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib48","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.psyneuen.2012.07.014","article-title":"Inhibition of 5\u03b1-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL\/6 mice","volume":"38","author":"Frau","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib49","series-title":"A\u00a0Dry Pipeline for Psychiatric Drugs","author":"Friedman","year":"2013"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib50","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/1557988314538445","article-title":"Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms","volume":"9","author":"Ganzer","year":"2015","journal-title":"Am. J. Men's Health"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pneurobio.2003.09.005","article-title":"Aromatase: a neuroprotective enzyme","volume":"71","author":"Garcia-Segura","year":"2003","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib52","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0306-4522(98)00340-6","article-title":"Aromatase expression by astrocytes after brain injury: implications for local estrogen formation in brain repair","volume":"89","author":"Garcia-Segura","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib53","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/1756287215592288","article-title":"Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy","volume":"7","author":"Gartrell","year":"2015","journal-title":"Therapeutic Advances in Urology"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/WNF.0000000000000017","article-title":"A\u00a0D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome","volume":"37","author":"Gilbert","year":"2014","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib56","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2125.1999.00843.x","article-title":"The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination","volume":"47","author":"Gisleskog","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib57","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1111\/bph.13243","article-title":"The D1CT-7 mouse model of Tourette syndrome displays sensorimotor gating deficits in response to spatial confinement","volume":"173","author":"Godar","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib58","doi-asserted-by":"crossref","first-page":"13512","DOI":"10.1073\/pnas.96.23.13512","article-title":"Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes","volume":"96","author":"Griffin","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.yfrne.2014.06.001","article-title":"GABAA receptor-acting neurosteroids: a role in the development and regulation of the stress response","volume":"36","author":"Gunn","year":"2015","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1517\/14740338.2013.742885","article-title":"Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation","volume":"12","author":"Gur","year":"2013","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1101\/lm.93105","article-title":"AMPA\/kainate, NMDA, and dopamine D1 receptor function in the nucleus accumbens core: a context-limited role in the encoding and consolidation of instrumental memory","volume":"12","author":"Hernandez","year":"2005","journal-title":"Learn. Mem."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib62","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.biopsych.2006.01.012","article-title":"Estrogen deficient male mice develop compulsive behavior","volume":"61","author":"Hill","year":"2007","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib63","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0960-0760(94)00187-Q","article-title":"FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) in\u00a0vitro effects on human and animal prostatic enzymes","volume":"52","author":"Hirosumi","year":"1995","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib64","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1073\/pnas.90.11.5277","article-title":"LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1","volume":"90","author":"Hirsch","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib65","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.biopsych.2005.01.040","article-title":"Impaired prepulse inhibition of acoustic startle in obsessive-compulsive disorder","volume":"57","author":"Hoenig","year":"2005","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003142","article-title":"Revolution stalled","volume":"4","author":"Hyman","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib67","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","article-title":"Research domain criteria (RDoC): toward a new classification framework for research on mental disorders","volume":"167","author":"Insel","year":"2010","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib68","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/wps.20227","article-title":"The NIMH experimental medicine initiative","volume":"14","author":"Insel","year":"2015","journal-title":"World Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib69","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.4088\/JCP.12m07887","article-title":"Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects","volume":"73","author":"Irwig","year":"2012","journal-title":"J.\u00a0Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib70","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nn.4245","article-title":"Resilience to chronic stress is mediated by noradrenergic regulation of dopamine neurons","volume":"19","author":"Isingrini","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib71","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/pros.10192","article-title":"Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism","volume":"54","author":"Ji","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1017\/S1121189X00001421","article-title":"The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys","volume":"18","author":"Kessler","year":"2009","journal-title":"Epidemiol. Psichiatr. Soc."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib73","doi-asserted-by":"crossref","first-page":"20162","DOI":"10.1074\/jbc.270.34.20162","article-title":"Substrate specificity, gene structure, and tissue-specific distribution of multiple human 3 alpha-hydroxysteroid dehydrogenases","volume":"270","author":"Khanna","year":"1995","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib74","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/cne.20760","article-title":"Localization of 5alpha-reductase in the rat main olfactory bulb","volume":"493","author":"Kiyokage","year":"2005","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib75","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1523\/JNEUROSCI.5186-03.2004","article-title":"Hippocampal synapses depend on hippocampal estrogen synthesis","volume":"24","author":"Kretz","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib76","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40474-016-0099-1","article-title":"Tourette syndrome and comorbid neuropsychiatric conditions","volume":"3","author":"Kumar","year":"2016","journal-title":"Curr Dev Disord Rep"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib77","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1210\/endo.137.7.8770891","article-title":"Ontogeny of 5 alpha-reductase (type 1) messenger ribonucleic acid expression in rat brain: early presence in germinal zones","volume":"137","author":"Lauber","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib78","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/0278-5846(93)90026-O","article-title":"Altered brain and pituitary androgen metabolism by prenatal, perinatal or pre- and postnatal finasteride, flutamide or dihydrotestosterone treatment in juvenile male rats","volume":"17","author":"Lephart","year":"1993","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib79","first-page":"1971","article-title":"Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha\/17 beta-HSD activity and cellular distribution","volume":"11","author":"Lin","year":"1997","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib81","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0301-0082(92)90025-A","article-title":"Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance","volume":"38","author":"Majewska","year":"1992","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib82","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0303-7207(94)90056-6","article-title":"Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase\/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey","volume":"104","author":"Martel","year":"1994","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib83","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0960-0760(92)90390-5","article-title":"Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues","volume":"41","author":"Martel","year":"1992","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib84","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/0960-0760(91)90031-Y","article-title":"Androgen metabolism in the brain","volume":"39","author":"Martini","year":"1991","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib85","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0039-128X(96)00176-6","article-title":"The regulation of 3 beta-hydroxysteroid dehydrogenase expression","volume":"62","author":"Mason","year":"1997","journal-title":"Steroids"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib86","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.brainresrev.2004.12.021","article-title":"Peripheral nerves: a target for the action of neuroactive steroids","volume":"48","author":"Melcangi","year":"2005","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib87","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0960-0760(98)00030-2","article-title":"The 5alpha-reductase in the central nervous system: expression and modes of control","volume":"65","author":"Melcangi","year":"1998","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib88","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jsbmb.2017.04.003","article-title":"Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients","volume":"171","author":"Melcangi","year":"2017","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib89","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jaac.2010.05.017","article-title":"Lifetime prevalence of mental disorders in U.S. Adolescents: results from the national comorbidity survey replication\u2013adolescent supplement (NCS-A)","volume":"49","author":"Merikangas","year":"2010","journal-title":"J.\u00a0Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib90","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.euroneuro.2015.01.015","article-title":"60 years of advances in neuropsychopharmacology for improving brain health, renewed hope for progress","volume":"25","author":"Millan","year":"2015","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib91","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0305-7372(89)90012-1","article-title":"Aromatase inhibitors in the treatment of advanced breast cancer","volume":"16","author":"Miller","year":"1989","journal-title":"Canc. Treat Rev."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib92","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1043-2760(98)00066-6","article-title":"17beta-hydroxysteroid dehydrogenases: physiological roles in health and disease","volume":"9","author":"Moghrabi","year":"1998","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib93","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.brainresrev.2007.10.011","article-title":"Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease?","volume":"57","author":"Morale","year":"2008","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib94","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fpsyt.2013.00021","article-title":"Perceived stress in obsessive-compulsive disorder is related with obsessive but not compulsive symptoms","volume":"4","author":"Morgado","year":"2013","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib95","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1038\/s41598-017-03649-1","article-title":"Allopregnanolone mediates the exacerbation of Tourette-like responses by acute stress in mouse models","volume":"7","author":"Mosher","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib96","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/026988119601000402","article-title":"Inhibition of basal and stress-induced dopamine release in the cerebral cortex and nucleus accumbens of freely moving rats by the neurosteroid allopregnanolone","volume":"10","author":"Motzo","year":"1996","journal-title":"J.\u00a0Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib97","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/mds.23810","article-title":"A\u00a0preliminary study of finasteride in Tourette syndrome","volume":"26","author":"Muroni","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib98","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1365-2826.1997.00582.x","article-title":"Differential effects of neuroactive steroids on somatostatin and dopamine secretion from primary hypothalamic cell cultures","volume":"9","author":"Murray","year":"1997","journal-title":"J.\u00a0Neuroendocrinol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib99","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1210\/endo-90-1-295","article-title":"Aromatization of androstenedione by the anterior hypothalamus of adult male and female rats","volume":"90","author":"Naftolin","year":"1972","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib100","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1210\/jcem-33-2-368","article-title":"Aromatization of androstenedione by the diencephalon","volume":"33","author":"Naftolin","year":"1971","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib101","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1677\/joe.0.0510795","article-title":"Aromatization of androstenedione by limbic system tissue from human foetuses","volume":"51","author":"Naftolin","year":"1971","journal-title":"J.\u00a0Endocrinol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib102","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1021\/bi00517a014","article-title":"Microsomal cytochrome P-450 from neonatal pig testis: two enzymatic activities (17 alpha-hydroxylase and c17,20-lyase) associated with one protein","volume":"20","author":"Nakajin","year":"1981","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib103","doi-asserted-by":"crossref","first-page":"18676","DOI":"10.1073\/pnas.1008911107","article-title":"Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine","volume":"107","author":"Navarro","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib104","first-page":"2055","article-title":"LY191704 inhibits type I steroid 5 alpha-reductase in human scalp","volume":"81","author":"Neubauer","year":"1996","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib105","author":"NIMH"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib106","doi-asserted-by":"crossref","DOI":"10.1038\/sj.mp.4001144","article-title":"A\u00a0transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry","volume":"7","author":"Nordstrom","year":"2002","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib107","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1176\/appi.ps.201400044","article-title":"The diminished pipeline for medications to treat mental health and substance use disorders","volume":"65","author":"O'Brien","year":"2014","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib108","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/138161211795049589","article-title":"Steroid 5\u03b1-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders","volume":"17","author":"Paba","year":"2011","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib109","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s12325-010-0041-6","article-title":"Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II","volume":"27","author":"Pais","year":"2010","journal-title":"Adv. Ther."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib110","first-page":"687","article-title":"Complex obsessive compulsive and impulsive symptoms in Tourette's syndrome","volume":"3","author":"Palumbo","year":"2007","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib111","doi-asserted-by":"crossref","first-page":"9044","DOI":"10.1073\/pnas.0502968102","article-title":"Substance P inhibits progesterone conversion to neuroactive metabolites in spinal sensory circuit: a potential component of nociception","volume":"102","author":"Patte-Mensah","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib112","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1523\/JNEUROSCI.3922-03.2004","article-title":"Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors","volume":"24","author":"Pei","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib113","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1006\/mcne.1994.1049","article-title":"Immunocytochemical localization of 5 alpha-reductase in rat brain","volume":"5","author":"Pelletier","year":"1994","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib114","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1042\/bj3510067","article-title":"Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones","volume":"351","author":"Penning","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib115","first-page":"63","article-title":"Structure\u2013function of human 3\u03b1-hydroxysteroid dehydrogenases: genes and proteins. Molecular and Cellular Endocrinology","volume":"vol. 215","author":"Penning","year":"2004"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib116","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1073\/pnas.80.14.4504","article-title":"Inhibition of a major NAD(P)-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins","volume":"80","author":"Penning","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib117","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0006-3223(01)01184-2","article-title":"Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania","volume":"50","author":"Perry","year":"2001","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib118","author":"PhRMA"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib119","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/FBP.0b013e32833d8ba0","article-title":"In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis","volume":"21","author":"Pinna","year":"2010","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0303-7207(97)04056-2","article-title":"Identification of type 1 5alpha-reductase in myelin membranes of male and female rat brain","volume":"129","author":"Poletti","year":"1997","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib121","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/archinte.1982.00340250097015","article-title":"Ketoconazole blocks testosterone synthesis","volume":"142","author":"Pont","year":"1982","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib122","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.psychres.2008.06.036","article-title":"The relationship between impulse control disorders and obsessive-compulsive disorder: a current understanding and future research directions","volume":"170","author":"Potenza","year":"2009","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib123","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1517\/14656566.7.17.2413","article-title":"Trilostane in advanced breast cancer","volume":"7","author":"Puddefoot","year":"2006","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib124","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1073\/pnas.88.10.4553","article-title":"Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain","volume":"88","author":"Purdy","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib125","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1124\/jpet.110.169854","article-title":"The testosterone-derived neurosteroid androstanediol is a positive allosteric modulator of GABAA receptors","volume":"334","author":"Reddy","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib126","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1210\/mend-5-8-1147","article-title":"Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase\/delta 5-delta 4-isomerase in human adrenals and gonads","volume":"5","author":"Rh\u00e9aume","year":"1991","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib127","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1460-9568.2002.02084.x","article-title":"The neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens","volume":"16","author":"Roug\u00e9-Pont","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11064-005-9004-8","article-title":"Synaptic plasticity in the hippocampus: effects of estrogen from the gonads or hippocampus?","volume":"31","author":"Rune","year":"2006","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib129","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.yfrne.2009.04.016","article-title":"Neuroprotective actions of brain aromatase","volume":"30","author":"Saldanha","year":"2009","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib130","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.clon.2017.03.010","article-title":"Impact of abiraterone acetate and enzalutamide on symptom burden of patients with chemotherapy-naive metastatic castration-resistant prostate cancer","volume":"29","author":"Salem","year":"2017","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib131","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/j.1755-5949.2010.00163.x","article-title":"Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders","volume":"16","author":"S\u00e1nchez","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib132","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1365-2265.1998.00390.x","article-title":"Aromatase in the human central nervous system","volume":"48","author":"Sasano","year":"1998","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib133","first-page":"1373","article-title":"MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen","volume":"82","author":"Schwartz","year":"1997","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"issue":"Suppl.\u00a0l","key":"10.1016\/j.neuropharm.2018.05.013_bib134","first-page":"S189","article-title":"Molecular biology and genetics of the 3 beta-hydroxysteroid dehydrogenase\/delta5-delta4 isomerase gene family","volume":"150","author":"Simard","year":"1996","journal-title":"J.\u00a0Endocrinol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.physiol.64.081601.142703","article-title":"Aromatase\u2013a brief overview","volume":"64","author":"Simpson","year":"2002","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib136","first-page":"480","article-title":"Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia","volume":"151","author":"Steiner","year":"1994","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib137","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1677\/joe.0.1600119","article-title":"Expression of 17beta-hydroxysteroid dehydrogenase types 1, 2, 3 and 4 in the human temporal lobe","volume":"160","author":"Stoffel-Wagner","year":"1999","journal-title":"J.\u00a0Endocrinol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib138","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0006-3223(02)01745-6","article-title":"Disrupted sensory gating in pathological gambling","volume":"54","author":"Stojanov","year":"2003","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib139","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1677\/joe.1.05889","article-title":"Dehydroepiandrosterone (DHEA) modulates GHRH, somatostatin and angiotensin II action at the pituitary level","volume":"185","author":"Su\u00e1rez","year":"2005","journal-title":"J.\u00a0Endocrinol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib140","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0022-4731(84)90264-4","article-title":"Inhibition of androgen metabolism and binding by a liposterolic extract of \u201cSerenoa repens B\u201d in human foreskin fibroblasts","volume":"20","author":"Sultan","year":"1984","journal-title":"J.\u00a0Steroid Biochem."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib141","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1100\/tsw.2011.57","article-title":"Sensory gating scales and premonitory urges in Tourette syndrome","volume":"11","author":"Sutherland","year":"2011","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib142","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/aps.2009.1","article-title":"Pharmacological effects of saw palmetto extract in the lower urinary tract","volume":"30","author":"Suzuki","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib143","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00213-006-0374-7","article-title":"Separable noradrenergic and dopaminergic regulation of prepulse inhibition in rats: implications for predictive validity and Tourette Syndrome","volume":"186","author":"Swerdlow","year":"2006","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib144","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0006-8993(90)91754-5","article-title":"GABAergic projection from nucleus accumbers to ventral pallidum mediates dopamine-induced sensorimotor gating deficits of acoustic startle in rats","volume":"532","author":"Swerdlow","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib145","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/026988119200600210","article-title":"The neural substrates of sensorimotor gating of the startle reflex: a review of recent findings and their implications","volume":"6","author":"Swerdlow","year":"1992","journal-title":"J.\u00a0Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib146","first-page":"69","article-title":"Preclinical models relevant to Tourette syndrome","volume":"99","author":"Swerdlow","year":"2006","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib147","doi-asserted-by":"crossref","first-page":"21321","DOI":"10.1074\/jbc.M501269200","article-title":"Identification of key amino acids responsible for the substantially higher affinities of human type 1 3beta-hydroxysteroid dehydrogenase\/isomerase (3beta-HSD1) for substrates, coenzymes, and inhibitors relative to human 3beta-HSD2","volume":"280","author":"Thomas","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib148","doi-asserted-by":"crossref","first-page":"42795","DOI":"10.1074\/jbc.M208537200","article-title":"Structure\/function relationships responsible for the kinetic differences between human type 1 and type 2 3beta-hydroxysteroid dehydrogenase and for the catalysis of the type 1 activity","volume":"277","author":"Thomas","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib149","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1096\/fj.02-1119com","article-title":"Differential regulation of steroid 5alpha-reductase isozymes expression by androgens in the adult rat brain","volume":"17","author":"Torres","year":"2003","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib150","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.yhbeh.2006.04.002","article-title":"Individual differences in estrogen receptor alpha in select brain nuclei are associated with individual differences in aggression","volume":"50","author":"Trainor","year":"2006","journal-title":"Horm. Behav."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib151","article-title":"Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction","volume":"30","author":"Traish","year":"2017","journal-title":"Horm. Mol. Biol. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib152","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0006-8993(96)00188-6","article-title":"Immunohistochemical presence of 5 alpha-reductase rat type 1-containing cells in the rat brain","volume":"722","author":"Tsuruo","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib153","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbrc.2016.07.019","article-title":"Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis","volume":"477","author":"Udhane","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib154","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/1097-0045(20001101)45:3<259::AID-PROS9>3.0.CO;2-G","article-title":"Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia","volume":"45","author":"Vacherot","year":"2000","journal-title":"Prostate"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib155","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jsbmb.2010.11.005","article-title":"CYP17 inhibitors for prostate cancer therapy","volume":"125","author":"Vasaitis","year":"2011","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib156","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2826.2006.01484.x","article-title":"Oestrogen synthesis in the hippocampus: role in axon outgrowth","volume":"18","author":"von Schassen","year":"2006","journal-title":"J.\u00a0Neuroendocrinol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib157","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamapsychiatry.2015.1743","article-title":"Whither research domain criteria (RDoC)?: the good, the bad, and the ugly","volume":"72","author":"Weinberger","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"64 Suppl.\u00a0l","key":"10.1016\/j.neuropharm.2018.05.013_bib158","first-page":"S93","article-title":"Dopamine and impulse control disorders in Parkinson's disease","volume":"2","author":"Weintraub","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2018.05.013_bib159","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2165\/00002512-199609040-00006","article-title":"Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer","volume":"9","author":"Wiseman","year":"1996","journal-title":"Drugs Aging"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib160","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.neuroscience.2005.11.054","article-title":"Aromatase expression in the human temporal cortex","volume":"138","author":"Yague","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.05.013_bib161","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jsbmb.2017.09.019","article-title":"Aromatase and neuroinflammation in rat focal brain ischemia","volume":"174","author":"Zhong","year":"2017","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818302326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818302326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T11:35:55Z","timestamp":1661254555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818302326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":160,"alternative-id":["S0028390818302326"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.013","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing steroidogenesis inhibitors for the therapy of neuropsychiatric disorders: Promises and caveats","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}